Search Results

Foresee Pharmaceuticals, announced that the first subject has been dosed in its Phase 1 clinical trial of FP-020 in Australia.

Foresee Pharmaceuticals announced that it will actively participate in and present two posters at the 2024 American Thoracic Society International Conference, which will be held in San Diego, CA, from May 17 to 22, 2024.

Foresee Pharmaceuticals, announces the positive safety review by the independent Data and Safety Monitoring Board for its Casppian Phase 3 registration study.

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an overlapping patient population.

Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”) provided highlights from its investor call regarding the rationale for the acquisition of the leptomeningeal metastases diagnostic platform “CNSide” and topline data from the FORESEE clinical trial.

Foresee Pharmaceuticals, announces that it has successfully completed an underwritten public offering of 17,500,000 shares of its common stock to the public at a price of NT$75 per share.

Foresee Pharmaceuticals Co., Ltd., announces that Bassem Elmankabadi, M.D. joins Foresee as a Senior Vice President of Clinical Development.

Foresee Pharmaceuticals, announces that the first patient has been dosed in the Casppian Phase 3 registration study.

Foresee Pharmaceuticals (TPEx: 6576), (“Foresee”) today announces that a new U.S. patent which covers CAMCEVI® (leuprolide mesylate) and its labeled indication is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as “the Orange Book”.

Foresee Pharmaceuticals, announced that the company will be presenting at the American Heart Association 2023 Annual Meeting taking place in Philadelphia, PA, from November 11-13, 2023.